BioSpace reviews some of the more interesting scientific studies recently published, including an unusual molecular chaperone implicated in Alzheimer’s disease.
Shares of Biohaven Pharmaceutical Holding Company Ltd. fell 16 percent after the company’s treatment for anxiety disorder failed to meet the main goal in a late-stage study.
Spain’s Grifols said the latest results from a clinical trial of the company’s Alzheimer’s treatment show positive effects by achieving a reduction of the disease’s progression in patients with mild and moderate conditions.
Biohaven Pharmaceutical will continue testing the company’s Alzheimer’s disease treatment troriluzole in a late-stage study as the drug had passed a so-called “futility analysis,” sending shares up 4.1 percent.
Researchers with the National Institute on Aging have published research of a gene variant – APO3 Christchurch (APOE3ch) – that appears to confer resistance to Alzheimer’s disease.
China granted conditional approval to the country’s first self-developed treatment for Alzheimer’s disease, a move that may point to revived opportunities in a therapeutic area where drugmakers have burned billions of dollars without yielding a validated new drug.
Biogen Inc.’s shock decision to bring the company’s experimental Alzheimer’s drug back from the scrap heap was born out of “top secret” meetings, non-disclosure agreements and six months of hashing over trial data with scientists, regulators and statisticians, researchers told Reuters.
Biogen Inc. revived plans to seek U.S. approval for the experimental Alzheimer’s treatment aducanumab, surprising investors.
Researchers at Washington University School of Medicine in St. Louis found further evidence that microglia are the key link between the accumulation of abnormal proteins, including beta-amyloid and tau, in the brain and the actual brain damage observed in Alzheimer’s patients.
Neurotrope Inc.’s shares tumbled nearly 80 percent after the company said the drug developer’s experimental Alzheimer’s disease treatment Bryostatin-1 did not meet the main goal of a mid-stage study.
